All Stories

  1. Divergence of C4A and C4B in first-episode psychosis: Insights from CSF and plasma immune profiling
  2. Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS
  3. Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population‐Based Observational Study
  4. Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study
  5. Changes in Multiple Sclerosis Clinical Care and Outcomes During the COVID‐19 Era: A Population‐Wide Study
  6. Correlates of patient reported quality of life in a large multiple sclerosis cohort encompassing the COVID-19 pandemic period
  7. A human pan-disease blood atlas of the circulating proteome
  8. Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis
  9. Beneficial impact of physical activity on multiple sclerosis disability progression
  10. Cardiovascular protein profiling in patients with first-episode psychosis
  11. Validation of the Swedish Multiple Sclerosis registry for pediatric-onset multiple sclerosis
  12. Fluid biomarkers of chronic traumatic brain injury
  13. Misdiagnosis and underdiagnosis of multiple sclerosis: A systematic review and meta-analysis
  14. Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study
  15. Trajectories of self-reported fatigue following initiation of multiple sclerosis disease-modifying therapy
  16. Neurofilaments as biomarkers in neurological disorders — towards clinical application
  17. Epidemiology of myasthenia gravis in Denmark, Finland and Sweden: a population-based observational study
  18. Real‐World Healthcare Cost Savings and Reduced Relapse Rate with Off‐Label Rituximab versus Disease‐Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A Nationwide Cost‐Effectiveness Study
  19. Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment
  20. COVID-19–Related Enhancement for the COMBAT-MS Study
  21. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
  22. Comparing the Safety and Effectiveness of Different Medicines to Treat Multiple Sclerosis – The COMBAT-MS Study
  23. Multiple Sclerosis, Disease-Modifying Therapies, and Infections
  24. Systemic Capillary Leak Syndrome With Cerebral Involvement in a C9orf72 Expansion Carrier
  25. Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis
  26. Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
  27. Comparing the Safety of Medicines to Treat MS during the COVID-19 Pandemic
  28. Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
  29. T cell responses at diagnosis of amyotrophic lateral sclerosis predict disease progression
  30. Low-dose rituximab should be used for treating MS in resource-limited settings: Yes
  31. The Karolinska NeuroCOVID study protocol: Neurocognitive impairment, biomarkers and advanced imaging in critical care survivors
  32. Demyelinating events following anti‐tumor necrosis factor alpha therapy: Rare but challenging to treat
  33. Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis
  34. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
  35. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
  36. Automatic deep learning multicontrast corpus callosum segmentation in multiple sclerosis
  37. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis
  38. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
  39. Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
  40. Screening for pathogenic neuronal autoantibodies in serum and CSF of patients with first-episode psychosis
  41. Association of Infectious Mononucleosis in Childhood and Adolescence With Risk for a Subsequent Multiple Sclerosis Diagnosis Among Siblings
  42. Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort
  43. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis
  44. Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis
  45. Risk of depression in multiple sclerosis across disease-modifying therapies
  46. ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records study
  47. Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury
  48. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance
  49. Small noncoding RNA profiling across cellular and biofluid compartments and their implications for multiple sclerosis immunopathology
  50. Neurofilament light chain as a marker for cortical atrophy in multiple sclerosis without radiological signs of disease activity
  51. Plasma bilirubin levels are reduced in first-episode psychosis patients and associates to working memory and duration of untreated psychosis
  52. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
  53. Fluid proteomics of CSF and serum reveal important neuroinflammatory proteins in blood–brain barrier disruption and outcome prediction following severe traumatic brain injury: a prospective, observational study
  54. Hospital-diagnosed infections before age 20 and risk of a subsequent multiple sclerosis diagnosis
  55. Deep Learning Corpus Callosum Segmentation as a Neurodegenerative Marker in Multiple Sclerosis
  56. Differential effects on blood and cerebrospinal fluid immune protein markers and kynurenine pathway metabolites from aerobic physical exercise in healthy subjects
  57. Cerebrospinal fluid brevican and neurocan fragment patterns in human traumatic brain injury
  58. Assessing the Preanalytical Variability of Plasma and Cerebrospinal Fluid Processing and Its Effects on Inflammation-Related Protein Biomarkers
  59. Associations between autoimmune diseases and amyotrophic lateral sclerosis: a register-based study
  60. Current and emerging disease modulatory therapies and treatment targets for multiple sclerosis
  61. Effect of Vitamin D on Experimental Autoimmune Neuroinflammation Is Dependent on Haplotypes Comprising Naturally Occurring Allelic Variants of CIITA (Mhc2ta)
  62. Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
  63. Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury
  64. Absence of Neuronal Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus
  65. Infections in patients with multiple sclerosis: A national cohort study in Sweden
  66. A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis
  67. Is the treatment of myasthenia gravis improving?
  68. The DQB1*03:02 Genotype and Treatment for Pain in People With and Without Multiple Sclerosis
  69. Neurological manifestations of coronavirus infections – a systematic review
  70. Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas-Casp8-Bid-axis
  71. The genetic architecture of human brainstem structures and their involvement in common brain disorders
  72. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis
  73. Non-infectious comorbidity in patients with multiple sclerosis: A national cohort study in Sweden
  74. Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate
  75. Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS
  76. Rituximab, MS, and pregnancy
  77. Enlarged perivascular spaces in multiple sclerosis on magnetic resonance imaging: a systematic review and meta-analysis
  78. Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
  79. CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects
  80. Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas/Casp8/Bid-axis
  81. Inflammation-related plasma and CSF biomarkers for multiple sclerosis
  82. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
  83. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
  84. Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis
  85. A Novel, Robust Method for Quantification of Multiple Kynurenine Pathway Metabolites in the Cerebrospinal Fluid
  86. Blood neurofilament light levels segregate treatment effects in multiple sclerosis
  87. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
  88. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity
  89. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels
  90. Creatinine and C-reactive protein in amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease
  91. Quantification of Plasma Kynurenine Metabolites Following One Bout of Sprint Interval Exercise
  92. MRI‐Based Manual versus Automated Corpus Callosum Volumetric Measurements in Multiple Sclerosis
  93. Retinal nerve fiber layer thickness associates with cognitive impairment and physical disability in multiple sclerosis
  94. Successful combined treatment with thymectomy, rituximab and tocilizumab for severe thymoma-associated multi autoimmune syndrome
  95. A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury
  96. Epilepsy in systemic lupus erythematosus: prevalence and risk factors
  97. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
  98. Common brain disorders are associated with heritable patterns of apparent aging of the brain
  99. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology
  100. Different epigenetic clocks reflect distinct pathophysiological features of multiple sclerosis
  101. Incidence of osmotic demyelination syndrome in Sweden: A nationwide study
  102. Non-parametric combination analysis of multiple data types enables detection of novel regulatory mechanisms in T cells of multiple sclerosis patients
  103. Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS
  104. Increased peripheral levels of TARC/CCL17 in first episode psychosis patients
  105. GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis
  106. Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
  107. Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk
  108. Rituximab treatment for multiple sclerosis
  109. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
  110. Neuronal methylome reveals CREB-associated neuro-axonal impairment in multiple sclerosis
  111. Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury
  112. Combining evidence from four immune cell types identifies DNA methylation patterns that implicate functionally distinct pathways during Multiple Sclerosis progression
  113. The association between multiple sclerosis and pain medications: Erratum.
  114. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
  115. Validation of the Swedish Multiple Sclerosis Register
  116. B cell alterations during BAFF inhibition with belimumab in SLE
  117. Morvan’s syndrome treated successfully with rituximab and lacosamide
  118. Author Correction: Multiple sclerosis
  119. Multiple sclerosis
  120. International consensus on quality standards for brain health-focused care in multiple sclerosis
  121. The association between multiple sclerosis and pain medications
  122. miR-31 regulates energy metabolism and is suppressed in T cells from patients with Sjögren's syndrome
  123. Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients
  124. Identification of MS-specific serum miRNAs in an international multicenter study
  125. Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
  126. Neurofilaments as biomarkers in neurological disorders
  127. Increased number of monocytes and plasma levels ofMCP‐1 andYKL‐40 in first‐episode psychosis
  128. Polygenic link between blood lipids and amyotrophic lateral sclerosis
  129. DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis
  130. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
  131. Depression and fatigue in multiple sclerosis: Relation to exposure to violence and cerebrospinal fluid immunomarkers
  132. Susceptibility to Oxidative Stress Is Determined by Genetic Background in Neuronal Cell Cultures
  133. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis – Yes
  134. The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations
  135. Impact of genetic risk loci for multiple sclerosis on expression of proximal genes in patients
  136. The Temporal Retinal Nerve Fiber Layer Thickness Is the Most Important Optical Coherence Tomography Estimate in Multiple Sclerosis
  137. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
  138. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
  139. Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
  140. Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis
  141. Novel genetic loci associated HLA-B*08:01 positive myasthenia gravis
  142. Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis
  143. Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes
  144. Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
  145. A minimal unified model of disease trajectories captures hallmarks of multiple sclerosis
  146. Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry
  147. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
  148. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab
  149. Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment
  150. CSF GABA is reduced in first-episode psychosis and associates to symptom severity
  151. Multiple Sclerosis—A Tuning Fork Still Required
  152. Population-based incidence and clinical characteristics of idiopathic intracranial hypertension
  153. Cross Talk in HEK293 Cells Between Nrf2, HIF, and NF-κB Activities upon Challenges with Redox Therapeutics Characterized with Single-Cell Resolution
  154. Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis – a case report
  155. Effects ofC2tagenetic polymorphisms on MHC class II expression and autoimmune diseases
  156. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing‐remitting multiple sclerosis
  157. Rituximab in multiple sclerosis
  158. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study
  159. Tryptophan Metabolism Along the Kynurenine Pathway Downstream of Toll‐like Receptor Stimulation in Peripheral Monocytes
  160. NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk
  161. Reply
  162. Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions
  163. Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society
  164. Absence of systemic oxidative stress and increased CSF prostaglandin F 2α in progressive MS
  165. T-cell activation and HLA-regulated response to smoking in the deep airways of patients with multiple sclerosis
  166. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
  167. Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis
  168. Complement Receptor 2 is increased in cerebrospinal fluid of multiple sclerosis patients and regulates C3 function
  169. No Evidence for Disease History as a Risk Factor for Narcolepsy after A(H1N1)pdm09 Vaccination
  170. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
  171. High-intensity resistance training in multiple sclerosis — An exploratory study of effects on immune markers in blood and cerebrospinal fluid, and on mood, fatigue, health-related quality of life, muscle strength, walking and cognition
  172. Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination
  173. Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis
  174. Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms
  175. Rituximab in paediatric onset multiple sclerosis: a case series
  176. Complement receptor 2 is up regulated in the spinal cord following nerve root injury and modulates the spinal cord response
  177. MicroRNAs as promising novel biomarkers and potential drug targets for inflammatory neurological diseases
  178. Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light
  179. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis
  180. Is a Cancer Diagnosis Associated with Subsequent Risk of Transient Global Amnesia?
  181. Complement Component C3 and Butyrylcholinesterase Activity Are Associated with Neurodegeneration and Clinical Disability in Multiple Sclerosis
  182. P300 amplitude and response speed relate to preserved cognitive function in relapsing–remitting multiple sclerosis
  183. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome
  184. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
  185. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes
  186. Risk factors for amyotrophic lateral sclerosis
  187. Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations
  188. Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis
  189. The autoimmune spectrum of myasthenia gravis: a Swedish population‐based study
  190. High interleukin-6 and impulsivity: determining the role of endophenotypes in attempted suicide
  191. Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells
  192. High Glutathione-S-transferase 4 alpha expression promotes nerve cell survival in neurodegenerative disorders
  193. Genetic study of Pandemrix-associated narcolepsy
  194. Methylome characterization of CD4+ T cells in multiple sclerosis — Establishing a role for miR-21 in autoimmune disease
  195. Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party
  196. Age-dependent effects on the treatment response of natalizumab in MS patients
  197. A changing treatment landscape for multiple sclerosis: challenges and opportunities
  198. Unbiased Expression Mapping Identifies a Link between the Complement and Cholinergic Systems in the Rat Central Nervous System
  199. Variability in the CIITA gene interacts with HLA in multiple sclerosis
  200. Phenotypes and Predictors of Pain Following Traumatic Spinal Cord Injury: A Prospective Study
  201. Variability in C-Type Lectin Receptors Regulates Neuropathic Pain-Like Behavior after Peripheral Nerve Injury
  202. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease
  203. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
  204. Regulated Extracellular Choline Acetyltransferase Activity— The Plausible Missing Link of the Distant Action of Acetylcholine in the Cholinergic Anti-Inflammatory Pathway
  205. Genetic variability in the rat Aplec C-type lectin gene cluster regulates lymphocyte trafficking and motor neuron survival after traumatic nerve root injury
  206. Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers
  207. Correction: Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression
  208. Naturally Occurring Variation in the Glutathione-S-Transferase 4 Gene Determines Neurodegeneration After Traumatic Brain Injury
  209. Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression
  210. The DQB1*03:02 HLA haplotype is associated with increased risk of chronic pain after inguinal hernia surgery and lumbar disc herniation
  211. Cognitive Impairment Has a Strong Relation to Nonsomatic Symptoms of Depression in Relapsing-Remitting Multiple Sclerosis
  212. Strain influences on inflammatory pathway activation, cell infiltration and complement cascade after traumatic brain injury in the rat
  213. In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106
  214. Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13
  215. Low vascular endothelial growth factor and interleukin-8 in cerebrospinal fluid of suicide attempters
  216. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs
  217. Age-dependent variation of genotypes in MHC II transactivator gene (CIITA) in controls and association to type 1 diabetes
  218. Risk for myasthenia gravis maps to a 151Pro→Ala change in TNIP1 and to human leukocyte antigen‐B*08
  219. The Calcitonin Receptor Gene Is a Candidate for Regulation of Susceptibility to Herpes simplex Type 1 Neuronal Infection Leading to Encephalitis in Rat
  220. Genetic and sex influence on neuropathic pain‐like behaviour after spinal cord injury in the rat
  221. Unmet medical needs with current standard treatments
  222. iNOS-mediated secondary inflammatory response differs between rat strains following experimental brain contusion
  223. Naturally Occurring Genetic Variability in Expression of Gsta4 is Associated with Differential Survival of Axotomized Rat Motoneurons
  224. Inflammatory and haemostatic markers in idiopathic intracranial hypertension
  225. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
  226. Concomitant autoimmunity in myasthenia gravis — Lack of association with IgA deficiency
  227. Both MHC and non-MHC genes regulate inflammation and T-cell response after traumatic brain injury
  228. The Expression of VEGF-A Is Down Regulated in Peripheral Blood Mononuclear Cells of Patients with Secondary Progressive Multiple Sclerosis
  229. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
  230. High levels of 15-oxygenated steroids in circulation of patients with multiple sclerosis: fact or fiction?
  231. Profiling of CD4+ T Cells with Epigenetic Immune Lineage Analysis
  232. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
  233. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
  234. Influence of Perineurial Cells and Toll-Like Receptors 2 and 9 on Herpes simplex Type 1 Entry to the Central Nervous System in Rat Encephalitis
  235. Genetic regulation of microglia activation, complement expression, and neurodegeneration in a rat model of traumatic brain injury
  236. Swedish natalizumab (Tysabri) multiple sclerosis surveillance study
  237. Genetic aspects in TBI
  238. Differential nerve injury-induced expression of MHC class II in the mouse correlates to genetic variability in the type I promoter of C2ta
  239. Identification of gene regions regulating inflammatory microglial response in the rat CNS after nerve injury
  240. Fine Mapping of Gene Regions Regulating Neurodegeneration
  241. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment‐sensitive biomarkers
  242. Inflammation and susceptibility to neurodegeneration: The use of unbiased genetics to decipher critical regulatory pathways
  243. Contrasting genetic effects of major histocompatibility complex on ischemic peripheral nerve and spinal cord injury in female rats
  244. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
  245. Both MHC and non-MHC genes regulate development of experimental neuropathic pain in rats
  246. Genetic analysis of neuropathic pain-like behavior following peripheral nerve injury suggests a role of the major histocompatibility complex in development of allodynia
  247. Vra4 Congenic Rats with Allelic Differences in the Class II Transactivator Gene Display Altered Susceptibility to Experimental Autoimmune Encephalomyelitis
  248. Host strain-dependent difference in susceptibility in a rat model of herpes simplex type 1 encephalitis
  249. The axon reaction: Identifying the genes that make a difference
  250. Recovery from spinal cord injury differs between rat strains in a major histocompatibility complex-independent manner
  251. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL
  252. Decreased Expression of VEGF‐A in Rat Experimental Autoimmune Encephalomyelitis and in Cerebrospinal Fluid Mononuclear Cells from Patients with Multiple Sclerosis
  253. Genetics of autoimmune neuroinflammation
  254. Decreased Expression of VEGF‐A in Rat Experimental Autoimmune Encephalomyelitis and in Cerebrospinal Fluid Mononuclear Cells from Patients with Multiple Sclerosis
  255. Genetically determined susceptibility to neurodegeneration is associated with expression of inflammatory genes
  256. Differential Expression of the Chemokine Receptors CX3CR1 and CCR1 by Microglia and Macrophages in Myelin-Oligodendrocyte-Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis
  257. Genetic Regulation of Nerve Avulsion-Induced Spinal Cord Inflammation
  258. Inflammation and neurodegeneration
  259. Expression of T cell immunoglobulin- and mucin-domain-containing molecules-1 and -3 (TIM-1 and -3) in the rat nervous and immune systems
  260. Genetic dissection of neurodegeneration and CNS inflammation
  261. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction
  262. A role for MHC class I molecules in synaptic plasticity and regeneration of neurons after axotomy
  263. T Cell Ig- and Mucin-Domain-Containing Molecule-3 (TIM-3) and TIM-1 Molecules Are Differentially Expressed on Human Th1 and Th2 Cells and in Cerebrospinal Fluid-Derived Mononuclear Cells in Multiple Sclerosis
  264. Prior poliomyelitis—IvIg treatment reduces proinflammatory cytokine production
  265. Increased Brain‐Derived Neurotrophic Factor Expression in White Blood Cells of Relapsing–Remitting Multiple Sclerosis Patients
  266. Harm or heal – divergent effects of autoimmune neuroinflammation?
  267. Properties of motoneurons underlying their regenerative capacity after axon lesions in the ventral funiculus or at the surface of the spinal cord
  268. Facial nerve lesion response; strain differences but no involvement of IFN-γ, STAT4 or STAT6
  269. Upregulation of VEGF-A Without Angiogenesis in a Mouse Model of Dilated Cardiomyopathy Caused by Mitochondrial Dysfunction
  270. Differential Expression of Neurotrophic Factors and Inflammatory Cytokines by Myelin Basic Protein‐Specific and Other Recruited T Cells Infiltrating the Central Nervous System during Experimental Autoimmune Encephalomyelitis
  271. Differential expression of multiple alternative spliceforms of the Men1 tumor suppressor gene in mouse
  272. Neuroinflammation in the rat - CNS cells and their role in the regulation of immune reactions
  273. Menin Interacts Directly with the Homeobox-Containing Protein Pem
  274. Neurodegeneration and glial activation patterns after mechanical nerve injury are differentially regulated by non‐MHC genes in congenic inbred rat strains
  275. Neurodegeneration and glial activation patterns after mechanical nerve injury are differentially regulated by non-MHC genes in congenic inbred rat strains
  276. Induction of VEGF and VEGF receptors in the spinal cord after mechanical spinal injury and prostaglandin administration
  277. Neuroprotection by Encephalomyelitis: Rescue of Mechanically Injured Neurons and Neurotrophin Production by CNS-Infiltrating T and Natural Killer Cells
  278. Genetics of rat neuroinflammation
  279. Molecular characterization of human and murine C11orf5, a new member of the FAUNA gene cluster
  280. Differential regulation of trophic factor receptor mRNAs in spinal motoneurons after sciatic nerve transection and ventral root avulsion in the rat
  281. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis
  282. Regulation of laminin-associated integrin subunit mRNAs in rat spinal motoneurons during postnatal development and after axonal injury
  283. Expression of nonclassical MHC class I (RT1-U) in certain neuronal populations of the central nervous system
  284. Expression of MHC class I heavy chain and β2-microglobulin in rat brainstem motoneurons and nigral dopaminergic neurons
  285. Non-MHC gene regulation of nerve root injury induced spinal cord inflammation and neuron death
  286. Restricted Expression Pattern ofvegf-din the Adult and Fetal Mouse: High Expression in the Embryonic Lung
  287. Expression of insulin-like growth factors and corresponding binding proteins (IGFBP 1-6) in rat spinal cord and peripheral nerve after axonal injuries
  288. Expression of insulin‐like growth factors and corresponding binding proteins (IGFBP 1–6) in rat spinal cord and peripheral nerve after axonal injuries
  289. Characterization of the mouse Men1 gene and its expression during development
  290. Characterization of the human synaptogyrin gene family
  291. Expression and chromosomal localization of the Requiem gene
  292. Expression of theBCL6Gene in the Pre- and Postnatal Mouse
  293. A comparative study of the expression patterns for vegf, vegf-b/vrf and vegf-c in the developing and adult mouse
  294. Mapping of the human Ca2+ channel β4 subunit to 2q22-23 and its expression in developing mouse
  295. Changes in the mRNA expression pattern, with special reference to calcitonin gene-related peptide, after axonal injuries in rat motoneurons depends on age and type of injury
  296. VAMP‐1 and VAMP‐2 gene expression in rat spinal motoneurones: differential regulation after neuronal injury
  297. Expression of LAZ3/BCL6 in follicular center (FC) B cells of reactive lymph nodes and FC-derived non-Hodgkin lymphomas
  298. Sequence and Expression of the Mouse Homologue to Human Phospholipase C β3 Neighboring Gene
  299. Differential subcellular localization of SNAP-25a and SNAP-25b RNA transcripts in spinal motoneurons and plasticity in expression after nerve injury
  300. Expression of the VEGF-Related Factor Gene in Pre- and Postnatal Mouse
  301. GDNF mRNA in Schwann cells and DRG satellite cells after chronic sciatic nerve injury
  302. Expression of the phosphoinositide-specific phospholipase Cβ3 gene in the rat
  303. Differential effects of combined trk receptor mutations on dorsal root ganglion and inner ear sensory neurons
  304. Prominent Expression of bFGF in Dorsal Root Ganglia after Axotomy
  305. Expression of NMDA Receptor mRNAs in Rat Motoneurons is Down-regulated after Axotomy
  306. Increase in α-CGRP and GAP-43 in aged motoneurons: A study of peptides, growth factors, and ChAT mRNA in the lumbar spinal cord of senescent rats with symptoms of hindlimb incapacities
  307. Fibroblast Growth Factors Regulate Calcitonin Gene-related Peptide mRNA Expression in Rat Motoneurons after Lesion and in Culture
  308. Adhesive/Repulsive Properties in the Injured Spinal Cord: Relation to Myelin Phagocytosis by Invading Macrophages
  309. Increased trkB mRNA expression by axotomized motoneurones
  310. trkC-like Immunoreactivity in the Primate Descending Serotoninergic System
  311. The peptidergic motoneurone
  312. Calcitonin Gene-Related Peptide in the Brain, Spinal Cord, and Some Peripheral Systems
  313. Calcitonin Gene-related Peptide (CGRP)-like Immunoreactivity and CGRP mRNA in Rat Spinal Cord Motoneurons after Different Types of Lesions